Trevor W Stone

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5044226/publications.pdf

Version: 2024-02-01

303 papers	13,161 citations	30551 56 h-index	34195 103 g-index
306 all docs	306 docs citations	306 times ranked	11586 citing authors

#	Article	IF	Citations
1	Editorial: Multiple Implications of the Kynurenine Pathway in Inflammatory Diseases: Diagnostic and Therapeutic Applications. Frontiers in Immunology, 2022, 13, 860867.	2.2	8
2	Induction of IDO1 and Kynurenine by Serine Proteases Subtilisin, Prostate Specific Antigen, CD26 and HtrA: A New Form of Immunosuppression?. Frontiers in Immunology, 2022, 13, 832989.	2.2	6
3	Disease status in human and experimental arthritis, and response to TNF blockade, is associated with MHC class II invariant chain (CD74) isoform expression. Journal of Autoimmunity, 2022, 128, 102810.	3.0	7
4	Quinolinic Acid and Related Excitotoxins: Mechanisms of Neurotoxicity and Disease Relevance. , 2021, , 1-22.		1
5	TLR expression profiles are a function of disease status in rheumatoid arthritis and experimental arthritis. Journal of Autoimmunity, 2021, 118, 102597.	3.0	19
6	Gut microbiota-derived vitamins â€“ underrated powers of a multipotent ally in psychiatric health and disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 107, 110240.	2.5	47
7	Pharmacological modulation of T cell immunity results in long-term remission of autoimmune arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	13
8	Relationships and Interactions between Ionotropic Glutamate Receptors and Nicotinic Receptors in the CNS. Neuroscience, 2021, 468, 321-365.	1.1	24
9	Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders. Complex Psychiatry, 2021, 7, 19-33.	1.3	10
10	Does kynurenic acid act on nicotinic receptors? An assessment of the evidence. Journal of Neurochemistry, 2020, 152, 627-649.	2.1	67
11	IDO activation, inflammation and musculoskeletal disease. Experimental Gerontology, 2020, 131, 110820.	1.2	33
12	Postural instability years after stroke. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 105038.	0.7	5
13	IDO and Kynurenine Metabolites in Peripheral and CNS Disorders. Frontiers in Immunology, 2020, 11, 388.	2.2	97
14	Dependence and Guidance Receptorsâ€”DCC and Neogeninâ€”In Partial EMT and the Actions of Serine Proteases. Frontiers in Oncology, 2020, 10, 94.	1.3	7
15	Serine protease modulation of Dependence Receptors and EMT protein expression. Cancer Biology and Therapy, 2019, 20, 349-367.	1.5	5
16	Obesity and Cancer: Existing and New Hypotheses for a Causal Connection. EBioMedicine, 2018, 30, 14-28.	2.7	179
17	Long term follow-up study of non-invasive brain stimulation (NBS) (rTMS and tDCS) in Parkinsonâ€™s disease (PD). Strong age-dependency in the effect of NBS. Brain Research Bulletin, 2018, 142, 78-87.	1.4	14
18	Kynurenine Pathway Activation in Human African Trypanosomiasis. Journal of Infectious Diseases, 2017, 215, jiw623.	1.9	5

#	Article	IF	Citations
19	Microbial carcinogenic toxins and dietary anti-cancer protectants. Cellular and Molecular Life Sciences, 2017, 74, 2627-2643.	2.4	13
20	Quinolinic acid induces neuritogenesis in <scp>SH</scp>â€<scp>SY</scp>5Y neuroblastoma cells independently of <scp>NMDA</scp> receptor activation. European Journal of Neuroscience, 2017, 45, 700-711.	1.2	15
21	The kynurenine pathway and the brain: Challenges, controversies and promises. Neuropharmacology, 2017, 112, 237-247.	2.0	290
22	The kynurenine pathway: Towards metabolic equilibrium. Neuropharmacology, 2017, 112, 235-236.	2.0	8
23	Tryptophan and kynurenines: continuing to court controversy. Clinical Science, 2016, 130, 1335-1337.	1.8	13
24	The Gut-Brain Axis, BDNF, NMDA and CNS Disorders. Neurochemical Research, 2016, 41, 2819-2835.	1.6	172
25	Dependence receptor involvement in subtilisin-induced long-term depression and in long-term potentiation. Neuroscience, 2016, 336, 49-62.	1.1	4
26	Kynurenine pathway metabolism following prenatal KMO inhibition and in Mecp2+/â˜ mice, using liquid chromatography-tandem mass spectrometry. Neurochemistry International, 2016, 100, 110-119.	1.9	7
27	Selective depletion of tumour suppressors Deleted in Colorectal Cancer (DCC) and neogenin by environmental and endogenous serine proteases: linking diet and cancer. BMC Cancer, 2016, 16, 772.	1.1	15
28	Altered hippocampal plasticity by prenatal kynurenine administration, kynurenine-3-monoxygenase (KMO) deletion or galantamine. Neuroscience, 2015, 310, 91-105.	1.1	45
29	Protection by the flavonoids quercetin and luteolin against peroxide- or menadione-induced oxidative stress in MC3T3-E1 osteoblast cells. Natural Product Research, 2015, 29, 1127-1132.	1.0	18
30	Kynurenines and Brain Development. , 2015, , 45-61.		1
31	Prenatal inhibition of the kynurenine pathway leads to structural changes in the hippocampus of adult rat offspring. European Journal of Neuroscience, 2014, 39, 1558-1571.	1.2	45
32	Modified neocortical and cerebellar protein expression and morphology in adult rats following prenatal inhibition of the kynurenine pathway. Brain Research, 2014, 1576, 1-17.	1.1	40
33	Quinolinate and Related Excitotoxins: Mechanisms of Neurotoxicity and Disease Relevance. , 2014, , 1543-1565.		0
34	Changes in synaptic transmission and protein expression in the brains of adult offspring after prenatal inhibition of the kynurenine pathway. Neuroscience, 2013, 254, 241-259.	1.1	47
35	An expanding range of targets for kynurenine metabolites of tryptophan. Trends in Pharmacological Sciences, 2013, 34, 136-143.	4.0	269
36	Involvement of the proteasome and caspase activation in hippocampal long-term depression induced by the serine protease subtilisin. Neuroscience, 2013, 231, 233-246.	1.1	8

#	Article	IF	Citations
37	The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders. British Journal of Pharmacology, 2013, 169, 1211-1227.	2.7	197
38	Prenatal inhibition of the tryptophanâ€“kynurenine pathway alters synaptic plasticity and protein expression in the rat hippocampus. Brain Research, 2013, 1504, 1-15.	1.1	55
39	Prenatal activation of maternal TLR3 receptors by viral-mimetic poly(I:C) modifies GluN2B expression in embryos and sonic hedgehog in offspring in the absence of kynurenine pathway activation. Immunopharmacology and Immunotoxicology, 2013, 35, 581-593.	1.1	9
40	Prenatal activation of Toll-like receptors-3 by administration of the viral mimetic poly(I:C) changes synaptic proteins, N-methyl-D-aspartate receptors and neurogenesis markers in offspring. Molecular Brain, 2012, 5, 22.	1.3	67
41	A novel dihydro-pyrazolo(3,4d)(1,2,4)triazolo(1,5a)pyrimidin-4-one (AJ23) is an antagonist at adenosine A1 receptors and enhances consolidation of step-down avoidance. Behavioural Brain Research, 2012, 234, 184-191.	1.2	8
42	Effects of ethylenediamine in rodent models of seizure, motor coordination and anxiety. Brain Research, 2012, 1473, 155-160.	1.1	2
43	Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection. FEBS Journal, 2012, 279, 1386-1397.	2.2	105
44	Involvement of kynurenines in Huntingtonâ€™s disease and stroke-induced brain damage. Journal of Neural Transmission, 2012, 119, 261-274.	1.4	51
45	Memory impairment in rats by hippocampal administration of the serine protease subtilisin. Behavioural Brain Research, 2011, 219, 63-67.	1.2	2
46	The serine protease subtilisin suppresses epileptiform activity in rat hippocampal slices and neocortex in vivo. Neuroscience, 2011, 199, 64-73.	1.1	0
47	Clonidine as an adenosine antagonist. Journal of Pharmacy and Pharmacology, 2011, 30, 792-793.	1.2	19
48	Î²-Kainic acid is not an amino acid antagonist. Journal of Pharmacy and Pharmacology, 2011, 37, 668-669.	1.2	4
49	Molecular changes associated with hippocampal long-lasting depression induced by the serine protease subtilisin-A. European Journal of Neuroscience, 2011, 34, 1241-1253.	1.2	5
50	Altered apoptotic responses in neurons lacking RhoB GTPase. European Journal of Neuroscience, 2011, 34, 1737-1746.	1.2	15
51	Kynurenine metabolism predicts cognitive function in patients following cardiac bypass and thoracic surgery. Journal of Neurochemistry, 2011, 119, 136-152.	2.1	45
52	Effects of ethylenediamine â€“ a putative GABA-releasing agent â€“ on rat hippocampal slices and neocortical activity in vivo. European Journal of Pharmacology, 2011, 650, 568-578.	1.7	1
53	Effects of AMPA and clomethiazole on spreading depression cycles in the rat neocortex in vivo. European Journal of Pharmacology, 2011, 653, 41-46.	1.7	8
54	Blood levels of kynurenines, interleukinâ€23 and soluble human leucocyte antigenâ€G at different stages of Huntingtonâ€™s disease. Journal of Neurochemistry, 2010, 112, 112-122.	2.1	72

#	Article	IF	Citations
55	Glutamateâ€induced depression of EPSPâ€“spike coupling in rat hippocampal CA1 neurons and modulation by adenosine receptors. European Journal of Neuroscience, 2010, 31, 1208-1218.	1.2	13
56	On the Biological Importance of the 3-hydroxyanthranilic Acid: Anthranilic Acid Ratio. International Journal of Tryptophan Research, 2010, 3, IJTR.S4282.	1.0	115
57	A Role for RhoB in Synaptic Plasticity and the Regulation of Neuronal Morphology. Journal of Neuroscience, 2010, 30, 3508-3517.	1.7	55
58	Kynurenine pathway inhibition reduces central nervous system inflammation in a model of human African trypanosomiasis. Brain, 2009, 132, 1259-1267.	3.7	52
59	Xanthine oxidase-induced neuronal death via the oxidation of NADH: Prevention by micromolar EDTA. Brain Research, 2009, 1280, 33-42.	1.1	11
60	Preconditioning with 4-aminopyridine protects cerebellar granule neurons against excitotoxicity. Brain Research, 2009, 1294, 165-175.	1.1	13
61	5-Hydroxyanthranilic Acid, a Tryptophan Metabolite, Generates Oxidative Stress and Neuronal Death via p38 Activation in Cultured Cerebellar Granule Neurones. Neurotoxicity Research, 2009, 15, 303-310.	1.3	49
62	KYNURENINE METABOLITES AND INFLAMMATION MARKERS IN DEPRESSED PATIENTS TREATED WITH FLUOXETINE OR COUNSELLING. Clinical and Experimental Pharmacology and Physiology, 2009, 36, 425-435.	0.9	52
63	Adenosine Receptors and Neurological Disease: Neuroprotection and Neurodegeneration. Handbook of Experimental Pharmacology, 2009, , 535-587.	0.9	178
64	Oxidative and nitrosative stress-induced neurotoxicity in primary cultured rat cerebellar granule neurons. Toxicology Letters, 2009, 189, S23.	0.4	0
65	Adenosine receptor ligands protect against a combination of apoptotic and necrotic cell death in cerebellar granule neurons. Experimental Brain Research, 2008, 186, 151-160.	0.7	23
66	Adenosine preconditions against ouabain but not against glutamate on CA1â€evoked potentials in rat hippocampal slices. European Journal of Neuroscience, 2008, 28, 2084-2098.	1.2	11
67	Resistance to kynurenic acid of the NMDA receptor-dependent toxicity of 3-nitropropionic acid and cyanide in cerebellar granule neurons. Brain Research, 2008, 1215, 200-207.	1.1	20
68	Prolonged exposures of cerebellar granule neurons to S-nitroso-N-acetylpenicillamine (SNAP) induce neuronal damage independently of peroxynitrite. Brain Research, 2008, 1230, 265-272.	1.1	15
69	Responses of differentiated MC3T3-E1 osteoblast-like cells to reactive oxygen species. European Journal of Pharmacology, 2008, 587, 35-41.	1.7	86
70	Preconditioning with NMDA protects against toxicity of 3-nitropropionic acid or glutamate in cultured cerebellar granule neurons. Neuroscience Letters, 2008, 440, 294-298.	1.0	13
71	Oxidative stress in neurodegeneration and available means of protection. Frontiers in Bioscience - Landmark, 2008, Volume, 3288.	3.0	103
72	New advances in the rehabilitation of CNS diseases applying rTMS. Expert Review of Neurotherapeutics, 2007, 7, 165-177.	1.4	31

#	Article	IF	Citations
73	Neurotoxicity of tryptophan metabolites. Biochemical Society Transactions, 2007, 35, 1287-1289.	1.6	36
74	Hydrogen peroxide mediates damage by xanthine and xanthine oxidase in cerebellar granule neuronal cultures. Neuroscience Letters, 2007, 416, 34-38.	1.0	38
75	The Elements of Murder: A History of Poison. By John Emsley. Oxford and New York: Oxford University Press. $30.00. xiii + 421 p; ill.; index. ISBN: 0â€19â€280599â€1. 2005.. Quarterly Review of Biology, 2007, 82, 142-143.	0.0	0
76	Pharmacology of the kynurenine pathway. International Congress Series, 2007, 1304, 298-304.	0.2	3
77	Interpretation of kynurenine pathway metabolism in osteoporosis. International Congress Series, 2007, 1304, 367-371.	0.2	0
78	Interleukin-1Î² but not tumor necrosis factor-Î± potentiates neuronal damage by quinolinic acid: Protection by an adenosine A2A receptor antagonist. Journal of Neuroscience Research, 2007, 85, 1077-1085.	1.3	64
79	Restored plasticity in a mouse model of neurofibromatosis typeâ€ƒ1 via inhibition of hyperactive ERK and CREB. European Journal of Neuroscience, 2007, 25, 99-105.	1.2	53
80	Kynurenic acid blocks nicotinic synaptic transmission to hippocampal interneurons in young rats. European Journal of Neuroscience, 2007, 25, 2656-2665.	1.2	90
81	Groupâ€ƒS8A serine proteases, including a novel enzyme cadeprin, induce longâ€‐lasting, metabotropic glutamate receptorâ€‐dependent synaptic depression in rat hippocampal slices. European Journal of Neuroscience, 2007, 26, 1870-1880.	1.2	9
82	Altered kynurenine metabolism correlates with infarct volume in stroke. European Journal of Neuroscience, 2007, 26, 2211-2221.	1.2	135
83	Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin. British Journal of Clinical Pharmacology, 2007, 64, 517-526.	1.1	86
84	Cell death in rat cerebellar granule neurons induced by hydrogen peroxide in vitro: Mechanisms and protection by adenosine receptor ligands. Brain Research, 2007, 1132, 193-202.	1.1	44
85	AMPA receptor activation reduces epileptiform activity in the rat neocortex. Brain Research, 2007, 1158, 151-157.	1.1	11
86	Tryptophan, adenosine, neurodegeneration and neuroprotection. Metabolic Brain Disease, 2007, 22, 337-352.	1.4	52
87	Purine Metabolism and Clinical Status of Patients with Rheumatoid Arthritis Treated with Dipyridamole. Nucleosides, Nucleotides and Nucleic Acids, 2006, 25, 1287-1290.	0.4	5
88	Hydrogen peroxide-induced oxidative stress in MC3T3-E1 cells: The effects of glutamate and protection by purines. Bone, 2006, 39, 542-551.	1.4	125
89	KYNURENINE PATHWAY METABOLISM IN PATIENTS WITH OSTEOPOROSIS AFTER 2 YEARS OF DRUG TREATMENT. Clinical and Experimental Pharmacology and Physiology, 2006, 33, 1078-1087.	0.9	75
90	Blood 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and melatonin levels in patients with either Huntington's disease or chronic brain injury. Journal of Neurochemistry, 2006, 97, 1078-1088.	2.1	39

#	Article	IF	Citations
91	Tryptophan metabolism and oxidative stress in patients with chronic brain injury. European Journal of Neurology, 2006, 13, 30-42.	1.7	107
92	Adenosine and cytokine levels following treatment of rheumatoid arthritis with dipyridamole. Rheumatology International, 2006, 27, 11-17.	1.5	9
93	NMDA-induced preconditioning attenuates synaptic plasticity in the rat hippocampus. Brain Research, 2006, 1073-1074, 183-189.	1.1	33
94	Differences in the neurochemical characteristics of the cortex and striatum of mice with cerebral malaria. Parasitology, 2005, 130, 23-29.	0.7	3
95	Tryptophan metabolism and oxidative stress in patients with Huntington's disease. Journal of Neurochemistry, 2005, 93, 611-623.	2.1	271
96	Selective subunit antagonists suggest an inhibitory relationship between NR2B and NR2A-subunit containing N-methyl-d-aspartate receptors in hippocampal slices. Experimental Brain Research, 2005, 162, 374-383.	0.7	46
97	Prolonged Survival of a Murine Model of Cerebral Malaria by Kynurenine Pathway Inhibition. Infection and Immunity, 2005, 73, 5249-5251.	1.0	87
98	Adenosine, neurodegeneration and neuroprotection. Neurological Research, 2005, 27, 161-168.	0.6	56
99	Barium, Glibenclamide and CGS21680 Prevent Adenosine A₁ Receptor Changes of ES Coupling and Spike Threshold. NeuroSignals, 2004, 13, 318-324.	0.5	3
100	Blockade of presynaptic adenosine A1 receptor responses by nitric oxide and superoxide in rat hippocampus. European Journal of Neuroscience, 2004, 20, 719-728.	1.2	10
101	Purine Modulation of Cytokine Release During Diuretic Therapy of Rheumatoid Arthritis. Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, 1107-1110.	0.4	5
102	Tryptophan Loading Induces Oxidative Stress. Free Radical Research, 2004, 38, 1167-1171.	1.5	73
103	Long-term follow-up study with repetitive transcranial magnetic stimulation (rTMS) in Parkinson's disease. Brain Research Bulletin, 2004, 64, 259-263.	1.4	32
104	Increased long-term potentiation in the CA1 region of rat hippocampus via modulation of GTPase signalling or inhibition of Rho kinase. Neuropharmacology, 2004, 46, 879-887.	2.0	39
105	The mechanism of inhibition by xanthine of adenosine A1-receptor responses in rat hippocampus. Neuroscience Letters, 2004, 365, 162-166.	1.0	1
106	Kynurenine, Neopterin and Lipid Peroxidation Levels in Ulcerative Colitis. Journal of Medical Sciences (Faisalabad, Pakistan), 2004, 4, 246-251.	0.0	1
107	Activation of Rho GTPases by synaptic transmission in the hippocampus. Journal of Neurochemistry, 2003, 87, 1309-1312.	2.1	45
108	Interactions between adenosine and metabotropic glutamate receptors in the rat hippocampal slice. British Journal of Pharmacology, 2003, 138, 1059-1068.	2.7	14

#	Article	IF	Citations
109	Pre-conditioning protection in the brain. British Journal of Pharmacology, 2003, 140, 229-230.	2.7	11
110	Electrochemical and in vitro evaluation of the redox-properties of kynurenine species. Biochemical and Biophysical Research Communications, 2003, 300, 719-724.	1.0	80
111	Distribution of Rho family GTPases in the adult rat hippocampus and cerebellum. Molecular Brain Research, 2003, 114, 1-8.	2.5	42
112	Tryptophan Metabolites and Brain Disorders. Clinical Chemistry and Laboratory Medicine, 2003, 41, 852-9.	1.4	139
113	LTP-induced depression of response to hypoxia in hippocampus: effects of adenosine receptor activation. NeuroReport, 2003, 14, 1809-1814.	0.6	2
114	Neuroprotective role of learning in dementia: a biological explanation. Journal of Alzheimer's Disease, 2003, 5, 91-104.	1.2	14
115	Purines and Neuroprotection. Advances in Experimental Medicine and Biology, 2003, 513, 249-280.	0.8	73
116	Kynurenine and Neopterin Levels in Patients with Rheumatoid Arthritis and Osteoporosis During Drug Treatment. Advances in Experimental Medicine and Biology, 2003, 527, 287-295.	0.8	50
117	Levels of Purine, Kynurenine and Lipid Peroxidation Products in Patients with Inflammatory Bowel Disease. Advances in Experimental Medicine and Biology, 2003, 527, 395-400.	0.8	65
118	Differential effects of remacemide and desglycinyl-remacemide on epileptiform burst firing in the rat hippocampal slice. Neuroscience Letters, 2002, 321, 33-36.	1.0	4
119	Long-term potentiation and adenosine sensitivity are unchanged in the AS/AGU protein kinase Cî³-deficient rat. Neuroscience Letters, 2002, 327, 165-168.	1.0	4
120	The pharmacological manipulation of glutamate receptors and neuroprotection. European Journal of Pharmacology, 2002, 447, 285-296.	1.7	92
121	Purine, kynurenine, neopterin and lipid peroxidation levels in inflammatory bowel disease. Journal of Biomedical Science, 2002, 9, 436-442.	2.6	65
122	Endogenous kynurenines as targets for drug discovery and development. Nature Reviews Drug Discovery, 2002, 1, 609-620.	21.5	646
123	Purine, kynurenine, neopterin and lipid peroxidation levels in inflammatory bowel disease. , 2002, 9, 436.		1
124	Antioxidants and fatty acids in the amelioration of rheumatoid arthritis and related disorders. British Journal of Nutrition, 2001, 85, 251-269.	1.2	202
125	Kynurenines in the CNS: from endogenous obscurity to therapeutic importance. Progress in Neurobiology, 2001, 64, 185-218.	2.8	282
126	Endogenous neurotoxins from tryptophan. Toxicon, 2001, 39, 61-73.	0.8	127

#	Article	IF	Citations
127	Neuroprotection by A2A receptor antagonists. Drug Development Research, 2001, 52, 323-330.	1.4	12
128	Long-term potentiation protects rat hippocampal slices from the effects of acute hypoxia. Brain Research, 2001, 907, 144-150.	1.1	25
129	Suppression of presynaptic responses to adenosine by activation of NMDA receptors. European Journal of Pharmacology, 2001, 427, 13-25.	1.7	34
130	Kynurenic acid antagonists and kynurenine pathway inhibitors. Expert Opinion on Investigational Drugs, 2001, 10, 633-645.	1.9	56
131	Inhibitors of the kynurenine pathway. European Journal of Medicinal Chemistry, 2000, 35, 179-186.	2.6	46
132	Complex hippocampal responses to ATP: fade due to nucleotidase inhibition and P2-receptor-mediated adenosine release. Brain Research, 2000, 860, 161-165.	1.1	7
133	NMDA-induced changes in a cortical network in vivo are prevented by AMPA. Brain Research, 2000, 869, 211-215.	1.1	14
134	Effects of clomethiazole on spreading depression in the rat hippocampal slice. European Journal of Pharmacology, 2000, 399, 29-34.	1.7	5
135	Characterisation of ATP-induced facilitation of transmission in rat hippocampus. European Journal of Pharmacology, 2000, 409, 159-166.	1.7	22
136	Possible mediation of quinolinic acid-induced hippocampal damage by reactive oxygen species. Amino Acids, 2000, 19, 275-281.	1.2	28
137	Suramin-sensitive suppression of paired-pulse inhibition by adenine nucleotides in rat hippocampal slices. Neuroscience Letters, 2000, 278, 45-48.	1.0	5
138	Pharmacological analysis of extracellular dopamine and metabolites in the striatum of conscious as/agu rats, mutants with locomotor disorder. Neuroscience, 2000, 100, 45-52.	1.1	5
139	Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends in Pharmacological Sciences, 2000, 21, 149-154.	4.0	177
140	Presynaptic P2 receptors?. Journal of the Autonomic Nervous System, 2000, 81, 244-248.	1.9	3
141	Occlusive responses to adenosine A1 receptor and muscarinic M2 receptor activation on hippocampal presynaptic terminals. Brain Research, 1999, 829, 193-196.	1.1	8
142	Prevention of muscimol-induced long-term depression by brain-derived neurotrophic factor. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1999, 23, 1215-1226.	2.5	3
143	Editorial. Journal of the Neurological Sciences, 1999, 163, 199-200.	0.3	5
144	Improvement in Parkinsonian symptoms after repetitive transcranial magnetic stimulation. Journal of the Neurological Sciences, 1999, 162, 179-184.	0.3	124

#	Article	IF	Citations
145	Chapter 20 Nucleotide and dinucleotide effects on rates of paroxysmal depolarising bursts in rat hippocampus. Progress in Brain Research, 1999, 120, 251-262.	0.9	2
146	Modulation by adenine nucleotides of epileptiform activity in the CA3 region of rat hippocampal slices. British Journal of Pharmacology, 1998, 123, 71-80.	2.7	37
147	Adenosine monophosphate as a mediator of ATP effects at P1 purinoceptors. British Journal of Pharmacology, 1998, 124, 818-824.	2.7	17
148	Epileptiform activity in supragranular and infragranular blocks of mouse neocortex. Epilepsy Research, 1998, 31, 29-38.	0.8	8
149	Protection against hippocampal kainate excitotoxicity by intracerebral administration of an adenosine A2A receptor antagonist. Brain Research, 1998, 800, 328-335.	1.1	118
150	Interaction between adenosine A1 and A2 receptor-mediated responses in the rat hippocampus in vitro. European Journal of Pharmacology, 1998, 362, 17-25.	1.7	71
151	Adenosine receptor-mediated inhibition of neurite outgrowth from cultured sensory neurons is via an A1 receptor and is reduced by nerve growth factor. Developmental Brain Research, 1998, 105, 167-173.	2.1	6
152	Protection by an Adenosine Analogue against Kainate-Induced Extrahippocampal Neuropathology. General Pharmacology, 1998, 31, 233-238.	0.7	10
153	Tolbutamide blocks postsynaptic but not presynaptic effects of adenosine on hippocampal CA1 neurones. Journal of Neural Transmission, 1998, 105, 161-172.	1.4	10
154	Purines and receptors. Trends in Neurosciences, 1998, 21, 51-52.	4.2	0
155	Increased expression of dendritic mRNA following the induction of long-term potentiation. Molecular Brain Research, 1998, 56, 38-44.	2.5	69
156	Comparison of an adenosine A1 receptor agonist and antagonist on the rat EEG. Neuroscience Letters, 1998, 244, 55-59.	1.0	9
157	Nitric oxide synthase inhibitors l-NAME and 7-nitroindazole protect rat hippocampus against kainate-induced excitotoxicity. Neuroscience Letters, 1998, 249, 75-78.	1.0	47
158	Protection against kainate-induced excitotoxicity by adenosine A2A receptor agonists and antagonists. Neuroscience, 1998, 85, 229-237.	1.1	114
159	The effects of adenine dinucleotides on epileptiform activity in the CA3 region of rat hippocampal slices. Neuroscience, 1998, 85, 217-228.	1.1	8
160	Extracellular levels of dopamine and its metabolite 3,4-dihydroxy-phenylacetic acid measured by microdialysis in the corpus striatum of conscious AS/AGU mutant rats. Neuroscience, 1998, 85, 323-325.	1.1	9
161	POTENTIATION OF MUSCIMOL-INDUCED LONG-TERM DEPRESSION BY BENZODIAZEPINES AND PREVENTION OR REVERSAL BY PREGNENOLONE SULFATE. Pharmacological Research, 1998, 38, 441-448.	3.1	9
162	Potential of Adenosine A2A Receptor Antagonists in the Treatment of Movement Disorders. CNS Drugs, 1998, 10, 311-320.	2.7	23

#	Article	IF	Citations
163	Changes in the concentration of amino acids in serum and cerebrospinal fluid of patients with Parkinson's disease. Journal of the Neurological Sciences, 1997, 151, 159-162.	0.3	68
164	The involvement of adenosine receptors in the effect of dizocilpine on mice in the elevated plus-maze. European Neuropsychopharmacology, 1997, 7, 267-273.	0.3	9
165	Alkylxanthine adenosine antagonists and epileptiform activity in rat hippocampal slices in vitro. Experimental Brain Research, 1997, 113, 303-310.	0.7	19
166	Purine modulation of dizocilpine effects on spontaneous alternation. Psychopharmacology, 1997, 130, 334-342.	1.5	27
167	Comparative sensitivity to adenosine of paired-pulse inhibition and single field potentials in the rat hippocampus. Neuroscience Letters, 1996, 209, 69-72.	1.0	1
168	Muscimol-induced long-term depression in the hippocampus: Lack of dependence on extracellular calcium. Neuroscience, 1996, 71, 581-588.	1.1	6
169	Maintenance of muscimol-induced long-term depression by neurosteroids. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1996, 20, 277-289.	2.5	3
170	Glutamate-independent long-term depression in rat hippocampus by activation of GABAA receptors. Life Sciences, 1996, 58, 1023-1030.	2.0	8
171	Interactions between ifenprodil and dizocilpine on mouse behaviour in models of anxiety and working memory. European Neuropsychopharmacology, 1996, 6, 311-316.	0.3	49
172	The contribution of adenosine to paired-pulse inhibition in the normal and disinhibited hippocampal slice. European Journal of Pharmacology, 1996, 317, 215-223.	1.7	10
173	Changes in hippocampal gene expression associated with the induction of long-term potentiation. Molecular Brain Research, 1996, 42, 123-127.	2.5	49
174	Ascorbate attenuates the systemic kainate-induced neurotoxicity in the rat hippocampus. Brain Research, 1996, 727, 133-144.	1.1	115
175	Effects of purine analogues on spontaneous alternation in mice. Psychopharmacology, 1996, 123, 250-257.	1.5	56
176	Potential role of adenosine antagonist therapy in pathological tremor disorders. , 1996, 72, 243-250.		36
177	Effect of adenosine on bicuculline-resistant paired-pulse inhibition in the rat hippocampal slice. Hippocampus, 1995, 5, 209-216.	0.9	2
178	Adenosine selectively depresses muscarinic compared with non-muscarinic receptor mediated depolarisation of the rat superior cervical ganglion. General Pharmacology, 1995, 26, 865-873.	0.7	5
179	Potentiation by neurosteroids of muscimol/adenosine interactions in rat hippocampus. Brain Research, 1995, 677, 311-318.	1.1	5
180	Efficacy of an adenosine antagonist, theophylline, in essential tremor: comparison with placebo and propranolol. Journal of the Neurological Sciences, 1995, 132, 129-132.	0.3	44

#	Article	IF	Citations
181	Delayed development of symptomatic improvement by (â^')-deprenyl in Parkinson's disease. Journal of the Neurological Sciences, 1995, 134, 143-145.	0.3	26
182	Anxiolytic activity of adenosine receptor activation in mice. British Journal of Pharmacology, 1995, 116, 2127-2133.	2.7	112
183	Modulation by adenosine of a neuronal inhibitory interaction in the rat hippocampus. Neuroscience Letters, 1995, 190, 167-170.	1.0	2
184	Further thoughts on â€œselectivityâ€•and â€œspecificityâ€• General Pharmacology, 1994, 25, 217.	0.7	0
185	Mechanism of the hippocampal loss of adenosine sensitivity in calcium-free media. Brain Research, 1994, 659, 221-225.	1.1	1
186	A paradoxical inhibitory effect of xanthines on hippocampal excitability in calcium-free media. Brain Research, 1994, 657, 300-306.	1.1	1
187	Interaction between adenosine and GABAA receptors on hippocampal neurones. Brain Research, 1994, 665, 229-236.	1.1	28
188	Blockade by 1,3-dipropyl-8-cyclopentylxanthine (CPX) of purine protection against kainate neurotoxicity. Brain Research, 1994, 644, 339-342.	1.1	9
189	Time course of purine protection against kainate-induced increase in hippocampal [3H]-PK11195 binding. Brain Research Bulletin, 1994, 34, 133-136.	1.4	3
190	Systemic ascorbate protects against kainate neurotoxicity. Biochemical Society Transactions, 1994, 22, 17S-17S.	1.6	4
191	Subtypes of NMDA receptors. General Pharmacology, 1993, 24, 825-832.	0.7	35
192	A purine analogue reduces kainate neurotoxicity in vivo. Biochemical Society Transactions, 1993, 21, 12S-12S.	1.6	0
193	The Ïƒ ligand 1,3-di-o-tolylguanidine depresses amino acid-induced excitation non-selectively in rat brain. European Journal of Pharmacology, 1992, 214, 169-173.	1.7	12
194	Nicotinylalanine increases cerebral kynurenic acid content and has anticonvulsant activity. General Pharmacology, 1992, 23, 235-239.	0.7	53
195	Kynurenine and glycine enhance neuronal sensitivity to N-methyl-D-aspartate. Life Sciences, 1991, 48, 765-772.	2.0	12
196	A comparison of excitotoxic lesions of the basal forebrain by kainate, quinolinate, ibotenate, Nâ€•methylâ€•<scp>d</scp>â€•aspartate or quisqualate, and the effects on toxicity of 2â€•aminoâ€•5â€•phosphonovaleric acid and kynurenic acid in the rat. British Journal of Pharmacology, 1991, 102, 904-908.	2.7	51
197	Receptors for adenosine and adenine nucleotides. General Pharmacology, 1991, 22, 25-31.	0.7	67
198	Depression of purine induced inhibition during NMDA receptor mediated activation of hippocampal pyramidal cells â€" an iontophoretic study. Brain Research, 1991, 564, 323-327.	1.1	10

#	Article	IF	Citations
199	The effect of theophylline on essential tremor: The possible role of GABA. Pharmacology Biochemistry and Behavior, 1991, 39, 345-349.	1.3	30
200	ELECTROPHARMACOLOGY OF ADENOSINE. , 1991, , 197-216.		10
201	Kynurenic acid antagonism of kainate following mossy fibre lesions of rat hippocampus. NeuroReport, 1990, 1, 218-220.	0.6	1
202	Adenosine Release. , 1990, , 173-223.		15
203	Introduction to neuropharmacology. Trends in Pharmacological Sciences, 1990, 11, 260-261.	4.0	1
204	Theophylline down-regulates adenosine receptor function. Brain Research, 1990, 509, 141-144.	1.1	12
205	NMDA-receptor-independent effects of low magnesium: involvement of adenosine. Brain Research, 1990, 508, 333-336.	1.1	9
206	Inhibition of adenosine responses of rat hippocampal neurones by nifedipine and BAYK 8644. Brain Research, 1990, 525, 315-318.	1.1	4
207	Activation of NMDA receptor-coupled channels suppresses the inhibitory action of adenosine on hippocampal slices. Brain Research, 1990, 530, 330-334.	1.1	40
208	Chronic benzodiazepine treatment and cortical responses to adenosine and GABA. Brain Research, 1990, 530, 353-357.	1.1	29
209	Possible subtypes of ATP receptor producing contraction of rat vas deferens, revealed by cross-desensitisation. General Pharmacology, 1989, 20, 61-64.	0.7	18
210	Quinolinic acid neurotoxicity: Protection by intracerebral phenylisopropyladenosine (PIA) and potentiation by hypotension. Neuroscience Letters, 1989, 101, 191-196.	1.0	42
211	Purine Receptors and their Pharmacological Roles. Advances in Drug Research, 1989, 18, 291-429.	0.8	27
212	Purine receptors and kynurenic acid modulate the somatosensory evoked potential in rat cerebral cortex. Electroencephalography and Clinical Neurophysiology, 1988, 69, 186-189.	0.3	9
213	Interactions of adenosine and magnesium on rat hippocampal slices. Brain Research, 1988, 463, 374-379.	1.1	22
214	Purine modulation of cholinomimetic responses in the rat hippocampal slice. Brain Research, 1988, 458, 106-114.	1.1	16
215	Presynaptic actions of adenosine are magnesium-dependent. Neuropharmacology, 1988, 27, 761-763.	2.0	17
216	Effects of anticonvulsants on responses to excitatory amino acids applied topically to rat cerebral cortex. General Pharmacology, 1988, 19, 455-462.	0.7	19

#	Article	IF	Citations
217	Interactions of carbamazepine, chlormethiazole and pentobarbitone with adenosine on hippocampal slices. General Pharmacology, 1988, 19, 67-72.	0.7	11
218	Comparison of kynurenic acid and 2-APV suppression of epileptiform activity in rat hippocampal slices. Neuroscience Letters, 1988, 84, 234-238.	1.0	28
219	Injection of baclofen into the ventromedial hypothalamus stimulates gastric motility in the rat. Neuropharmacology, 1987, 26, 1191-1194.	2.0	15
220	Direct excitatory effects of neuropeptide Y (NPY) on rat hippocampal neurones in vitro. Brain Research, 1987, 408, 295-298.	1.1	52
221	Amino acid receptor nomenclature. Trends in Neurosciences, 1987, 10, 74-75.	4.2	4
222	Involvement of receptors in the augmenting response in rat neocortex. Neuroscience Letters, 1987, 78, 323-327.	1.0	8
223	Purine effects on (3H)-clonidine binding to rat brain. Biochemical Pharmacology, 1986, 35, 1757-1760.	2.0	1
224	Inhibition by benzodiazepines and Î²-carbolines of brief (5 seconds) synaptosomal accumulation of [3H]-adenosine. Biochemical Pharmacology, 1986, 35, 1760-1762.	2.0	15
225	The effect of kainic, quinolinic and Î²-kainic acids on the release of endogenous amino acids from rat brain slices. Biochemical Pharmacology, 1986, 35, 3631-3635.	2.0	32
226	The effects of adenosine on receptor sensitivity in the rat vas deferens. European Journal of Pharmacology, 1986, 132, 11-19.	1.7	8
227	Effects of topically applied excitatory amino acids on evoked potentials and single cell activity in rat cerebral cortex. European Journal of Pharmacology, 1986, 121, 337-343.	1.7	24
228	Postsynaptic action of kynurenic acid in the rat dentate gyrus. Neuroscience Letters, 1986, 66, 96-100.	1.0	14
229	The relative potencies of (â^')-2-amino-5-phosphonovalerate and (â^')-2-amino-7-phosphonoheptanoate as antagonists of N-methylaspartate and quinolinic acids and repetitive spikes in rat hippocampal slices. Brain Research, 1986, 381, 195-198.	1.1	22
230	Activity of Î²-kainic acid on neocortical neurons in vivo and hippocampal neurons in vitro. Neuroscience, 1986, 17, 629-633.	1.1	5
231	O-Phosphohomoserine, a naturally occurring analogue of phosphonate amino acid antagonists, is an N-methyl-d-aspartate (NMDA) antagonist in rat hippocampus. Neuroscience Letters, 1986, 68, 249-251.	1.0	4
232	The psychopharmacology of epilepsy. Trends in Pharmacological Sciences, 1986, 7, 36.	4.0	0
233	Activation of thermogenesis of brown fat in rats by Baclofen. Neuropharmacology, 1986, 25, 627-631.	2.0	36
234	The suppression of hippocampal potentials by the benzodiazepine antagonist Ro 15-1788 may be mediated by purines. Brain Research, 1986, 380, 379-382.	1.1	19

#	Article	IF	Citations
235	Quinolinic acid and other kynurenines in the central nervous system. Neuroscience, 1985, 15, 597-617.	1.1	303
236	The role of kynurenines in diabetes mellitus. Medical Hypotheses, 1985, 18, 371-376.	0.8	28
237	Differences of neuronal sensitivity to amino acids and related compounds in the rat hippocampal slice. Neuroscience Letters, 1985, 59, 313-317.	1.0	18
238	Cyclohexyladenosine binding in rat striatum. Brain Research, 1985, 334, 385-388.	1.1	11
239	Effect of copper on the binding and electrophysiological actions of cyclohexyladenosine. Brain Research, 1985, 336, 187-189.	1.1	2
240	Excitant activity of methyl derivatives of quinolinic acid on rat cortical neurones. British Journal of Pharmacology, 1984, 81, 175-181.	2.7	28
241	The action of gamma-aminobutyric acid (GABA) and ethylenediamine (EDA) on Limulus and Helix central neurones and rat cerebellar and sympathetic ganglion neurones. General Pharmacology, 1984, 15, 497-504.	0.7	5
242	Quinolinic acid and kynurenic acid. Trends in Pharmacological Sciences, 1984, 5, 215.	4.0	6
243	Ethylenediamine as a GABA-mimetic. Trends in Pharmacological Sciences, 1984, 5, 241-243.	4.0	10
244	Purine receptors classification: a point for discussion. Trends in Pharmacological Sciences, 1984, 5, 492-493.	4.0	27
245	Actions of excitatory amino acids and kynurenic acid in the primate hippocampus: A preliminary study. Neuroscience Letters, 1984, 52, 335-340.	1.0	49
246	CYCLIC NUCLEOTIDES AND ADENYLATE CYCLASE IN BRAIN: ELECTROPHYSIOLOGICAL STUDIES. , 1984, , 171-189.		0
247	A comparison of the anticonvulsant potency of (Â±) 2-amino-5-phosphono-pentanoic acid and (Â±) 2-amino-7-phosphonoheptanoic acid. Neuroscience, 1983, 9, 925-930.	1.1	93
248	Inhibition of adenosine accumulation by a CNS benzodiazepine antagonist (Ro 15â€“1788) and a peripheral benzodiazepine receptor ligand (Ro 05â€“4864). Neuroscience Letters, 1983, 41, 183-188.	1.0	27
249	Quisqualic acid excitation of cortical neurones is selectively antagonized by streptomycin. Brain Research, 1983, 260, 347-349.	1.1	10
250	Quinolinic acid: regional variations in neuronal sensitivity. Brain Research, 1983, 259, 172-176.	1.1	147
251	Actions of 6-aminonicotinamide of benzodiazepine receptors in rat CNS. Neuroscience Letters, 1983, 40, 51-54.	1.0	0
252	Benzodiazepine inhibition of adenosine uptake is not prevented by benzodiazepine antagonists. European Journal of Pharmacology, 1983, 87, 121-126.	1.7	26

#	Article	IF	Citations
253	Actions of TRH and cyclo-(His-Pro) on spontaneous and evoked activity of cortical neurones. European Journal of Pharmacology, 1983, 92, 113-118.	1.7	21
254	On the interaction of 2-amino-7-phosphono-heptanoic acid and quinolinic acid in mice. European Journal of Pharmacology, 1983, 89, 297-300.	1.7	10
255	Interactions of Adenosine with other Agents. , 1983, , 467-477.		8
256	Nanomolar concentrations of propranolol inhibit GABA-stimulated benzodiazepine binding to rat cerebral cortex. Neuroscience Letters, 1982, 29, 159-162.	1.0	6
257	Isomers of 2-amino-7-phosphonoheptanoic acid as antagonists of neuronal excitants. Neuroscience Letters, 1982, 32, 65-68.	1.0	58
258	Textbook of clinical neuropharmacology. Trends in Pharmacological Sciences, 1982, 3, 342.	4.0	0
259	Adenosine symposium. Trends in Pharmacological Sciences, 1982, 3, 423-425.	4.0	1
260	Purine receptors involved in the depression of neuronal firing in cerebral cortex. Brain Research, 1982, 248, 367-370.	1.1	40
261	An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Research, 1982, 247, 184-187.	1.1	787
262	Actions of adenine dinucleotides on the vas deferens, guinea-pig taenia caeci and bladder. European Journal of Pharmacology, 1981, 75, 93-102.	1.7	53
263	Factors affecting the release of purines from mouse cerebral cortex: Potassium removal and metabolic inhibitors. Biochemical Pharmacology, 1981, 30, 1239-1243.	2.0	9
264	Methylxanthines modulate adenosine release from slices of cerebral cortex. Brain Research, 1981, 207, 421-431.	1.1	25
265	Adenine dinucleotide effects on rat cortical neurones. Brain Research, 1981, 229, 241-245.	1.1	47
266	Phosphonate analogues of carboxylic acids as aminoacid antagonists on rat cortical neurones. Neuroscience Letters, 1981, 23, 333-336.	1.0	131
267	Differential blockade of ATP, noradrenaline and electrically evoked contractions of the rat vas deferens by nifedipine. European Journal of Pharmacology, 1981, 74, 373-376.	1.7	32
268	Physiological roles for adenosine and adenosine 5â€²-triphosphate in the nervous system. Neuroscience, 1981, 6, 523-555.	1.1	489
269	Neuronal responses to ethylenediamine: Preferential blockade by bicuculline. Neuroscience Letters, 1981, 23, 325-327.	1.0	40
270	Activity of the enantiomers of 2-amino-5-phosphono-valeric acid as stereospecific antagonists of excitatory aminoacids. Neuroscience, 1981, 6, 2249-2252.	1.1	45

#	Article	IF	Citations
271	Activation of brown adipose tissue thermogenesis by the ventromedial hypothalamus. Nature, 1981, 289, 401-402.	13.7	309
272	Chronic methylxanthine treatment in rats: A comparison of Wistar and Fischer 344 strains. Pharmacology Biochemistry and Behavior, 1981, 14, 827-830.	1.3	18
273	The action of adenosine on noradrenergic neuronal inhibition induced by stimulation of locus coeruleus. Brain Research, 1980, 183, 367-376.	1.1	44
274	Adenosine and related compounds do not affect nerve terminal excitability in rat CNS. Brain Research, 1980, 182, 198-200.	1.1	13
275	Purinergic transmission in the CNS?. Trends in Pharmacological Sciences, 1980, 1, 273-275.	4.0	8
276	Effects of adenosine and related compounds on an inhibitory process in rat cerebral cortex. Experimental Neurology, 1980, 70, 556-566.	2.0	12
277	ADENOSINE INHIBITION OF Î³â€AMINOBUTYRIC ACID RELEASE FROM SLICES OF RAT CEREBRAL CORTEX. British Journal of Pharmacology, 1980, 69, 107-112.	2.7	156
278	BLOCKADE OF STRIATAL NEURONE RESPONSES TO MORPHINE BY AMINOPHYLLINE: EVIDENCE FOR ADENOSINE MEDIATION OF OPIATE ACTION. British Journal of Pharmacology, 1980, 69, 131-137.	2.7	45
279	Neuronal (Na+,K+)-ATPase and the release of purines from mouse and rat cerebral cortex. Neuroscience Letters, 1980, 20, 217-221.	1.0	11
280	Is adenosine the mediator of opiate action on neuronal firing rate?. Nature, 1979, 281, 227-228.	13.7	50
281	AMINO ACIDS AS NEUROTRANSMITTERS OF CORTICOFUGAL NEURONES IN THE RAT: A COMPARISON OF GLUTAMATE AND ASPARTATE. British Journal of Pharmacology, 1979, 67, 545-551.	2.7	64
282	GLUTAMATE AS THE NEUROTRANSMITTER OF CEREBELLAR GRANULE CELLS IN THE RAT: ELECTROPHYSIOLOGICAL EVIDENCE. British Journal of Pharmacology, 1979, 66, 291-296.	2.7	96
283	The neuromuscular and vascular hypotheses of muscular dystrophy: A possible link via adenine nucleotides and phosphate. Medical Hypotheses, 1979, 5, 1105-1111.	0.8	3
284	Antidepressant drugs potentiate suppression by adenosine of neuronal firing in rat cerebral cortex. Neuroscience Letters, 1979, 11, 93-97.	1.0	23
285	Selective antagonism of amino acids by Î±-aminoadipate on pyramidal tract neurones but not Purkinje cells. Brain Research, 1979, 166, 217-220.	1.1	19
286	Coenzyme A or adenosine inhibiting acetylcholine release?. Nature, 1978, 274, 721-721.	13.7	2
287	Neuronal responses to extracellularly applied cyclic AMP: Role of the adenosine receptor. Experientia, 1978, 34, 481-482.	1.2	22
288	ANTAGONISM BY CLONIDINE OF NEURONAL DEPRESSANT RESPONSES TO ADENOSINE, ADENOSINEâ€5â€²â€MONOPHOSPHATE AND ADENOSINE TRIPHOSPHATE. British Journal of Pharmacology, 1978, 64, 369-374.	2.7	45

#	Article	IF	Citations
289	Biochemical and electropharmaceutical studies with tricyclic antidepressants in rat and guinea-pig cerebral cortex. Life Sciences, 1978, 23, 2621-2626.	2.0	23
290	Interactions between guanine derivatives and norepinephrine on neurones of the mammalian cerebral cortex. Brain Research, 1978, 155, 187-191.	1.1	6
291	An electrophysiological demonstration of a synergistic interaction between norepinephrine and adenosine in the cerebral cortex. Brain Research, 1978, 147, 396-400.	1.1	38
292	Possible Roles for Purine Compounds in Neuronal Adaptation. Biochemical Society Transactions, 1978, 6, 858-862.	1.6	17
293	Evidence for a non-dopaminergic action of amantadine. Neuroscience Letters, 1977, 4, 343-346.	1.0	8
294	Blockade of central Î²-adrenergic receptors by tazolol (1-isopropylamino-3-(2-thiazoloxy)-2-propanol). Life Sciences, 1977, 21, 1655-1663.	2.0	5
295	Drugs and central synaptic transmission. Trends in Biochemical Sciences, 1977, 2, 72.	3.7	0
296	Cardiovascular modulation of central neuronal activity. Brain Research, 1976, 105, 333-336.	1.1	0
297	Depression of neurones in the rat cerebral cortex by leptazol. Experientia, 1976, 32, 92-93.	1.2	3
298	Responses of central neurones to amantadine: comparison with dopamine and amphetamine. Brain Research, 1975, 85, 126-129.	1.1	23
299	Further evidence for a dopamine receptor stimulating action of an ergot alkaloid. Brain Research, 1974, 72, 177-180.	1.1	24
300	Pharmacology of pyramidal tract cells in the cerebral cortex. Naunyn-Schmiedeberg's Archives of Pharmacology, 1973, 278, 333-346.	1.4	71
301	A bipolar electrode for localized directional stimulation. Experientia, 1973, 29, 666-667.	1.2	4
302	Strychnine, morphine and monoamine depression. Life Sciences, 1973, 13, 125-133.	2.0	2
303	Are Noradrenaline Excitations Artefacts ?. Nature, 1971, 234, 145-146.	13.7	41